A new treatment without chemotherapy for indolent clinical forms of mantle cell lymphoma
A new treatment without chemotherapy is effective in treating indolent clinical forms of mantle cell lymphoma.
A study led by researchers from the Hospital Clínic‑IDIBAPS shows that a new treatment without chemotherapy is effective in treating indolent clinical forms of mantle cell lymphoma. The combination of ibrutinib and rituximab produced complete responses in over 80% of patients and allowed most patients to discontinue treatment after two years, demonstrating a promising alternative to conventional immunochemotherapy.
The results suggest that a less toxic, frontline therapy using ibrutinib and rituximab can provide durable disease control and enable treatment cessation, potentially improving quality of life and reducing long‑term toxicity in this patient subgroup.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
- Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.
- Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa